The ATHENA study is a phase II trial exploring the activity and safety of the association of the anti-PD-L1 atezolizumab and the anti-VEGF-A/B monoclonal antibody bevacizumab in platinum-resistant R/M HNSCC [25]. Here, CD274 is linked to head and neck squamous cell carcinoma.